1. Michener WM, Farmer RG, Mortimer EA. Long-term prognosis of ulcerative colitis with onset in childhood or adolescence. J Clin Gastroenterol. 1979;1: 301-305.
2.
2. Michener WM, Whelan G, Greenstreet RL, Farmer RG. Comparison of the clinical features of Crohn's disease and ulcerative colitis with onset in childhood or adolescence. Cleve ClinJMed. 1982;49:13-16.
3.
3. MarkowitzJ, Grancher K, RosaJ, et al. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1993;16:373-380.
5. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology. 1988;95:1523-1527.
6.
6. MarkowitzJ, Daum F. Growth impairment in pediatric inflammatory bowel disease. Am J Gastroenterol. 1994;89: 319-326.
7.
7. MarkowitzJ, Grancher K, RosaJ, et al. Growth failure in pediatric inflammatory bowel disease [see comments].J Pediatr Castroenterol Nutr. 1993;16:373-380.
9. Schwartz AG, Targan SR, Saxon A, Weinstein WM. Sulfasalazine-induced exacerbation of ulcerative colitis. N Engi/JMed. 1982;306:409-412.
10.
10. Halsted CH, Gandhi G, Tamura T. Sulfasalazine inhibits the absorption of folates in ulcerative colitis. NEnglJ Med. 1981;305:1513-1517.
11.
11. Hayashi AH, GiacomantonioJM, Lau HY, Gillis DA. Balloon catheter dilatation for hypertrophic pyloric stenosis. JPediatrSurg. 1990;25:1119-1121.
12.
12. Hanauer SB, Krawitt EL, Robinson M, et al. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group [see comments]. Am J Gastroenterol. 1993;88:1343-1351.
13.
13. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's Disease: a meta-analysis. AmJ Gastroenterol. 1994;89:2116-2124.
14.
14. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) [see comments]. Gastroenterology. 1993;104: 435-439.
15.
15. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group [see comments]. Gastroenterology. 1993;104:1293-1301.
16.
16. Griffiths A, Koletzko S, Sylvester F, et al. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. JPediatr GastroenterolNutr. 1993;17:186-192.
17.
17. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study [see comments]. Ann Intern Med. 1991;115:350-355.
18.
18. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. DigDis Sci. 1995;40:296-304.
19.
19. Anonymous. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med. 1996;124:204-211.
20.
20. Modigliani R, ColombelJF, DupasJL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1996;110:688-693.
21.
21. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group [see comments]. Gastroenterology. 1992;103:363-368.
22.
22. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology. 1995;108:345-349.
23.
23. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995;109:404-413.
24.
24. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection [see comments]. Gastroenterology. 1995;108:1617-1621.
25.
25. Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology. 1985;88:681-684.
26.
26. Spirt MJ. Antibiotics in inflammatory bowel disease: new choices for an old disease. Am J Gastroenterol. 1994;89: 974-978.
27.
27. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group [see comments]. N Engl J Med. 1994;331:836-841.
28.
28. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease [see comments]. N Engl J Med. 1994;331:842-845.
29.
29. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996;110:45-51.
30.
30. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo-controlled oneyear study. Gut. 1996;39:82-86.
31.
31. LeBoff MS. Is prolonged use of corticosteroids safe in patients with Crohn's disease?Inflammatory Bowel Diseases. 1997;3:169-173.
32.
32. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77:847-869.
33.
33. Smith RC, RhodesJ, Heatley RV, et al. Low-dose steroids and clinical relapse in Crohn's disease: a controlled trial. Gut. 1978;19:606-610.
34.
34. Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. Scand J Gastroenterol. 1976;11:651-656.
35.
35. Malchow H, Ewe K, BrandesJW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86: 249-266.
36.
36. Bello C, Goldstein F, Thornton J. Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol. 1991;86: 460-466.
37.
37. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide CIR for maintenance of remission in ileocecal Crohn's disease. A European multicenter placebo-controlled trial for 12 months. Gastroenterology. 1994;106:A722-A722 (abstract).
38.
38. Lennard-Jones JE, Misiewicz JJ, Connel AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet. 1965;1:188-189.
39.
39. Cocco AE, Mendeloff Al. An evaluation of intermittent corticosteroid therapy in the management of ulcerative colitis. Johns Hopkins Medj1967;120:162-169.
40.
40. MarkowitzJ, RosaJ, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease [see comments]. Gastroenterology. 1990;99:1347-1351.
41.
41. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease.J Pediatr. 1990;117:809-814.
42.
42. Shanahan F, Bernstein CN. Safety of low-dose purine analogues in inflammatory bowel disease. Gastroenterology. 1994;107:1905-1906.
43.
43. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. NEnglJ Med. 1980;302:981-987.
44.
44. Markowitz J, Grancher K, Mandel F, Daum F. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of North American Society for Pediatric Gastroenterology and Nutrition. AmJ Gastroenterol. 1993;88:44-48.
45.
45. Perrault J, Greseth JL, Tremaine WJ. 6-mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease. Mayo Clin Proc. 1991;66:480-484.
46.
46. O'Brien J, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease [see comments]. Gastroenterology. 1991;101:39-46.
47.
47. Treem WR, Davis PM, Hyams JS. Cyclosporine treatment of severe ulcerative colitis in children. JPediatr. 1991;119:994-997.
49. Treem WR, Cohen J, Davis PM, et al. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 1995;38:474-479.
50.
50. Sartor RB. Cyclosporine therapy for inflammatory bowel disease [editorial; comment]. N Engl J Med. 1994;330:1897-1898.
51.
51. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflammatory Bowel Diseases. 1995;1:48-63.
52.
52. Feagan BG, McDonaldJW, RochonJ, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators [see comments]. NEnglJMed. 1994;330:1846-1851.
53.
53. BrynskovJ, Freund L, Rasmussen SN, et al. A placebo-controlled, doubleblind, randomized trial of cyclosporine therapy in active chronic Crohn's disease [see comments]. N EnglJ Med. 1989;321:845-850.
54.
54. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci. 1994;39:374-380.
55.
55. Sarigol S, Caulfield M, Wyllie R, et al. Ileal pouch-anal anastomosis in children with ulcerative colitis. Inflammatory Bowel Diseases. 1996;2:82-87.
56.
56. Davies G, Evans CM, Shand WS, Walker-Smith JA. Surgery for Crohn's disease in childhood: influence of site of disease and operative procedure on outcome. BrJSurg. 1990;77:891-894.
57.
57. Oliva L, Wyllie R, Caulfield M, et al. The results of stricutreplasty in pediatric patients with multifacal Crohn's disease. J Pediatr Gastroenterol Nutr. 1994;18:306-310.
58.
58. Ruuska T, Savilahti E, Maki M, Ormala T. Exclusive whole protein enteral diet versus prednisilone in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr. 1994;19:175-180.
59.
59. Gonzalez-Huix F, de Leon R, Fernandex-Banares F, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroidcontrolled trial. Gut. 1993;34:778-782.
60.
60. Aiges H, MarkowitzJ, RosaJ, Daum F. Home nocturnal supplemental nasogastric feedings in growth retarded adolescents with Crohn's disease. Gastroenterology. 1989;97:905-910.
61.
61. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease.JPediatr Gastroenterol Nutr. 1993;17:75-81.
62.
62. Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology. 1988;94:603-610.
63.
63. Kleinman RE, Balistreri WF, Heyman MB, et al. Nutritional support for pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1989;8:8-12.
64.
64. Polk DB, HattnerJA, KernerJAJr.Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohn's disease. JPENJ Parenter Enteral Nutr. 1992;16:499-504.
65.
65. Lochs H, Steinhardt HJ, Klaus-Wentz B, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV [see comments]. Gastroenterology. 1991;101:881-888.
66.
66. Rigaud D, CosnesJ, Le Quintrec Y, et al. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut. 1991;32:1492-1497.
67.
67. Gorard DA, Hunt JB, Payne-James JJ, et al. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut. 1993;34:1198-1202.
68.
68. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology. 1995;108:1056-1067.
